% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Mar 19, 2013 10:51 AM Flag

    Possible revenues for an orphan drug

    Now that the "game changer" with multi billion dollar potential has been sold to Shire(will be),perhaps we can post about what moves the share price....Wedbush says both indications will yield 240 Million to 290 million of this billion dollar potential drug" ( boilerplate...opportuity.........90% of orphan drugs produce revenues of 200 M or less. ...if Insmed meets Wedbushs numbers and assuming 4 times revenues ( not profits) you come up with a $24 dollar share price or.....the price Insmed was selling for in 2009

    That is of course assuming Insmed is not required to do a Phase3 test in 2014 for NTM, and that Insmed spends the money on a Phase3 trial in the U.S for CF. and .........discounting possible dilutions

    ok Im not trading today ...Fed meeting lots of shorts in the markets now
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.76-0.24(-1.71%)Oct 27 4:00 PMEDT